Interestingly, authors reported that, in mice, combination of telaglenastat with immune checkpoint inhibitors against PD-1 or CTLA-4 increased the number of tumor-infiltrating T cells and the expression of genes associated with IFN-γ signaling (255). Here, CTLA4 is linked to neoplasm.